Bruce Neal's Publications

About Bruce Neal's Publications

Executive Director, The George Institute for Global Health, Australia

  • Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

    The Lancet Date published:

  • Sodium, Blood Pressure, and the Likely Massive Avoidable Burden of Cardiovascular Disease

    Circulation Date published:

  • Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

    Kidney International Date published:

  • Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial

    Cardiovascular Research Date published:

  • Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis

    The Lancet Oncology Date published:

  • Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

    American Heart Journal Date published:

  • Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS Program

    Endocrinology, Diabetes & Metabolism Date published:

  • The impact of baseline potassium intake on the dose-response relation between sodium reduction and blood pressure change: systematic review and meta-analysis of randomized trials

    Journal of Human Hypertension Date published:

  • An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials

    International Journal of Cardiology Date published:

  • Sodium Reduction: How Big Might the Risks and Benefits Be?

    Heart, Lung and Circulation Date published:

  • Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria

    Clinical Journal of the American Society of Nephrology Date published:

  • Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program

    ESC Heart Failure Date published:

  • Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program

    American Journal of Kidney Diseases Date published:

  • Estimating the potential impact of Australia’s reformulation programme on households’ sodium purchases

    BMJ Nutrition, Prevention & Health Date published:

  • Protocol for a randomized controlled trial to test the acceptability and adherence to 6-months of walnut supplementation in Chinese adults at high risk of cardiovascular disease

    Nutrition Journal Date published:

  • Ultra-low-dose quadruple combination blood pressure-lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol

    American Heart Journal Date published: